Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC

Zhifeng Zhao†, Yiming Zhu†, Xiaochun Ni†, Jiayun Lin†, Hongjie Li†, Lei Zheng†, Chihao Zhang†, Xiaoliang Qi†, Haizhong Huo†, Xiaolou Lou†, Qiang Fan†, Yongyang Bao* and Meng Luo†*

Abstract

Background: The gamma-glutamyl transferase (GGT) to alanine aminotransferase (ALT) ratio has been reported as an effective predictor of the severity of hepatitis and HCC. The purpose of this study was to determine the role of the GGT/ALT ratio in the prediction of vascular invasion and survival outcomes in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).

Methods: The risk factors for vascular invasion were determined by univariate/multivariate logistic analysis. The cut-off value of GGT/ALT in predicting vascular invasion was calculated using the receiver operating characteristic (ROC) curve. The prognostic value of GGT/ALT was examined by Cox analysis and Kaplan–Meier curves. Sensitivity analysis, such as subgroup analysis and propensity score matching (PSM), was performed to reduce potential confounding bias.

Results: A high GGT/ALT ratio was identified as an independent risk factor for vascular invasion (P = 0.03). The correlation analysis suggested that higher GGT/ALT was associated with more severe tumour burdens, including vascular invasion (P < 0.001), tumour volume > 5 cm (P < 0.001), poor pathological differentiation (P = 0.042), more severe BCLC (P < 0.001) and ALBI grade (P = 0.007). In the survival analysis, a high GGT/ALT ratio was associated with poor overall survival (OS) (HR: 1.38; 95% CI 1.03, 1.87; P < 0.0001) and disease-free survival (DFS) (HR: 1.32; 95% CI 1.03, 1.87; P < 0.0001). In the subgroup analysis, similar results were consistently observed across most subgroups. In PSM analysis, GGT/ALT remained independently associated with vascular invasion (OR, 186; 95% CI 1.23, 3.33).

Conclusion: The GGT/ALT ratio was a potential effective factor in the prediction of vascular invasion and prognosis in patients with HBV-related HCC.

Keywords: Gamma-glutamyl transferase, Alanine aminotransferase, Vascular invasion, Hepatocellular carcinoma

Introduction

In 2018, liver cancer was ranked as the sixth most common cancer and fourth leading cause of cancer-related death in the world, with 841,000 new cases and 782,000 deaths each year [1], among which 85–90% of cases belong to hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) is one of the major risk factors associated with HCC worldwide, especially in China [2].

At present, the treatment of HCC mainly involves chemotherapy, surgical resection and liver transplantation [3]. However, high rates of metastasis and recurrence
after surgery severely deteriorate the prognosis; in this process, vascular invasion accounts for the leading cause [4, 5]. Kunutsor et al. [6] demonstrated that intrahepatic vascular invasion was the prevalent cause of postoperative recurrence and cancer-related death in HCC patients. Therefore, accurate and effective assessment of vascular invasion before surgery is strongly needed to guide treatment options.

Currently, preoperative assessment of vascular invasion is mainly performed by computed tomography (CT), while laboratory tests are equally indispensable for adjuvant assessment. Risk factors for HCC vascular invasion include HBV infection, tumour size, multifocal localization, α-fetoprotein (AFP), γ-glutamyl transferase (GGT), alanine transaminase (ALT), etc. [4, 7, 8]. As a major aetiological factor, HBV infection changes the hepatic microenvironment, induces an inflammatory response, and promotes angiogenesis and vascular invasion. Several studies have confirmed the correlation between HBV infection and vascular invasion in HCC [9, 10]. Therefore, it is possible to determine vascular invasion and poor prognosis by assessing HBV severity, in which GGT and ALT have been widely investigated with considerable potential.

A high GGT/ALT ratio was initially found to be prognostically associated with worse condition and treatment response in viral hepatitis [11, 12]. Additional studies indicated that GGT/ALT was a positive predictor of HCC [13, 14]. However, those previous studies emphasized the prediction of hepatitis or HCC more, while the predictive effect of GGT/ALT on vascular invasion in HBV-related HCC is still unknown. Considering the vital role of hepatitis B in vascular invasion of HCC combined with the diagnostic value of GGT/ALT in hepatitis, the aim of our study was to confirm whether GGT/ALT is a risk factor for vascular invasion, cancer severity and outcomes in HBV-related HCC patients.

A total of 558 patients were enrolled in our study. First, potential risk factors for vascular invasion were identified using univariate and multivariate logistic analyses. The cut-off value of GGT/ALT in predicting vascular invasion was calculated using the receiver operating characteristic (ROC) curve. The prognostic value of GGT/ALT was examined by Cox analysis and Kaplan–Meier curves. Finally, subgroup analysis and propensity score matching (PSM) were used to eliminate confounding bias.

Method

Patients

Clinical data were collected from 558 patients with HBV-infected HCC who underwent surgical resection at Zhongshan Hospital affiliated with Fudan University (Shanghai, China) between August 1, 2011, and July 31, 2017. The inclusion criteria were as follows: (1) HCC was diagnosed by postoperative pathological examinations; (2) history of HBV infection; (3) patient underwent hepatectomy as initial treatment in Zhongshan Hospital; (4) aged over 18; and (5) no distant metastasis was detected. The exclusion criteria were as follows: (1) patients with alcoholic liver disease, hepatitis C or other primary liver chronic diseases except hepatitis B; (2) patients with other concomitant or previous cancers; and (3) patients with preoperative anticancer treatment such as transcatheter chemoembolization (TACE), chemotherapy, radiotherapy, etc.; (4) incomplete clinical and follow-up medical records.

After discharge, patients were followed up regularly every three months for the first three years and every six months thereafter. Serum biomarkers of tumour and hepatitis B were examined periodically, and abdominal contrast-enhanced CT, ultrasound, hepatic arteriogram or invasive examination were performed as needed. Overall survival (OS) was defined as the interval between the date of surgery and death or the last follow-up. Disease-free survival (DFS) was defined as the time interval between the date of surgery and the date of confirmed HCC recurrence or the date of last follow-up. The last follow-up ended on July 31, 2020. The study was approved by the Ethical Committees of Zhongshan Hospital of Fudan University.

Data collection

The following clinical data of HBV-infected HCC patients were collected in our study: (1) demographic data, including age and sex; (2) preoperative laboratory examination, including GGT, ALT, albumin, AFP and total bilirubin (TB); (3) tumour information evaluated by imaging tests, pathological examinations and scoring systems, including vascular invasion, tumour size, tumour multifocality, tumour capsule, pathological differentiation, cirrhosis, Barcelona Clinic Liver Cancer (BCLC) classification, and albumin-bilirubin (ALBI) grade; and (4) postoperative follow-up data including OS and DFS.

Definition

Laboratory examination data were manipulated by the laboratory Department of Zhongshan Hospital. HBV infection was defined as a positive test for hepatitis B virus surface antigen (HBsAg). The normal ranges of laboratory tests included ALT ≤ 56 U/L, GGT ≤ 50 U/L, albumin ≤ 40 g/L, TB ≤ 20 μmol/L, and AFP ≤ 400 ng/mL. Tumour size, tumour number, tumour capsule, pathological differentiation, cirrhosis and vascular invasion were confirmed by CT imaging combined with postoperative pathological examination. Each specimen was reviewed independently by two liver pathologists.
Microvascular invasion (MVI) is defined as microscopically confirmed tumour clusters in the vascular cavity [4]. The assessment of BCLC classification was performed as described previously [15]. Pathological differentiation was conducted using the Edmondson grading system [16]. ALBI grade was employed as a powerful tool for survival analysis in HCC patients, with a specific calculation process as described previously [17].

**Statistical analysis**

The data analysis was performed by R (R Statistical Software, version 4.0.2). The optimal GGT/ALT cut-off value of the receiver operating characteristic (ROC) curve was identified by calculating the maximum value of the Youden index. Categorical variables were assessed using Pearson chi-square test or Fisher’s exact test as appropriate. A logistic regression model was used for univariate and multivariate analyses. Cumulative survival rates were calculated by Kaplan–Meier analysis and compared with the log-rank method. The Cox method was used for univariate and multivariate survival analysis. Subgroup analysis was conducted to compare the heterogeneity of prediction in subgroups. \( P < 0.05 \) was considered statistically significant.

**Propensity score matching (PSM)**

PSM was used to reduce bias. The matching process was applied by the minimum distance scoring method combined with matched 1:1 matching within the high and low GGT/ALT groups. Logistic regression models were used to calculate propensity scores, including age, sex, ALT, albumin, TB, AFP, cirrhosis, tumour size, number of tumours, tumour capsule, pathological differentiation, BCLC classification, GGT and ALBI grade. By using the nearest-neighbour PSM algorithm, 93 patients in the high GGT/ALT group were matched 1:1 with 93 patients in the low GGT/ALT group. After matching, univariate logistic analysis was performed between the high and low GGT/ALT groups to predict vascular invasion.

**Results**

**General clinical characteristics**

In our study, 558 HCC patients with HBV infection were involved (Fig. 1). All of the patients received tumour resection surgery, and general clinical characteristics are summarized in Table 1. As a consequence of the results, the majority of patients exhibited ALT within the normal range \((\leq 56 \text{ U/L}, 84.41\% \text{ vs. } 15.59\%)\), while the majority of the GGT distributions were comparable between the low (48.75%) and high groups (51.25%). As a sign of poor prognosis, vascular invasion was not combined with most of the patients (69.71% vs. 30.29%). The other principal components included younger than 60 years (75.63% vs. 24.37%), men (84.95% vs. 15.05%), albumin > 40 g/L (51.97% vs. 48.03%), TB < 20 \(\mu\)mol/L (90.14% vs. 9.86%), AFP < 400 ng/mL (72.04% vs. 27.96%), cirrhosis (79.21% vs. 20.79%), tumour size \((\leq 5 \text{ cm}, 64.52\% \text{ vs. } 35.48\%)\), solitary tumours (83.87% vs. 16.13%), tumour capsule absence (63.44% vs. 36.56%), and moderate/poor differentiation (67.03% vs. 32.97%). In the BCLC classification, grades A, B, and C accounted for 61.65%, 31.54% and 6.81%, respectively. In ALBI grade, grades A and B accounted for 71.51% and 28.50%, respectively. This finding indicated a significant probability of malignant HBV-associated HCC.

**Identification of risk factors for vascular invasion**

Logistic univariate analysis and multivariate analysis were conducted to identify the predictive risk factors for vascular invasion. In univariate analysis, GGT/ALT values were associated positively with vascular invasion (OR: 1.96; 95% CI 1.34, 2.87; \( P = 0.03 \)), the other indicators included age (OR: 0.46; 95% CI 0.29, 0.74; \( P = 0.001 \)), serum AFP (OR: 2.3; 95% CI 1.56, 3.4; \( P = 0.001 \)), tumour size (OR: 2.96; 95% CI 2.04, 4.31; \( P < 0.001 \)), tumour number (OR: 1.68; 95% CI 1.05, 2.68; \( P = 0.032 \)), tumour capsule (OR: 1.79; 95% CI 1.24, 2.59; \( P = 0.002 \)), pathological
Table 1  Distribution of clinical variables among total, high and low GGT/ALT groups

| Variables                  | Total (n = 558) | Low (n = 365) | High (n = 193) | P     |
|---------------------------|----------------|--------------|---------------|-------|
| Age, n (%)                |                |              |               | 1     |
| ≤ 60                      | 422 (75.63)    | 291 (75.58)  | 131 (75.72)   |       |
| > 60                      | 136 (24.37)    | 94 (24.42)   | 42 (24.28)    |       |
| Sex, n (%)                |                |              |               | 0.003 |
| Female                    | 84 (15.05)     | 70 (18.18)   | 14 (8.09)     |       |
| Male                      | 474 (84.95)    | 315 (81.82)  | 159 (91.91)   |       |
| ALT, n(%)                 |                |              | < 0.001       |       |
| ≤ 56                      | 471 (84.41)    | 299 (77.66)  | 172 (99.42)   |       |
| > 56                      | 87 (15.59)     | 86 (22.34)   | 1 (0.58)      |       |
| Albumin, n (%)            |                |              | 0.057         |       |
| ≤ 40                      | 268 (48.03)    | 211 (54.81)  | 79 (45.66)    |       |
| > 40                      | 290 (51.97)    | 174 (45.19)  | 94 (54.34)    |       |
| TB, n (%)                 |                |              | 0.657         |       |
| ≤ 20                      | 503 (90.14)    | 349 (90.65)  | 154 (89.02)   |       |
| > 20                      | 55 (9.86)      | 36 (9.35)    | 19 (10.98)    |       |
| AFP, n (%)                |                |              | 0.399         |       |
| ≤ 400                     | 402 (72.04)    | 282 (73.25)  | 120 (69.36)   |       |
| > 400                     | 156 (27.96)    | 103 (26.75)  | 53 (30.64)    |       |
| Cirrhosis, n (%)          |                |              | 0.904         |       |
| No                        | 116 (20.79)    | 79 (20.52)   | 37 (21.39)    |       |
| Yes                       | 442 (79.21)    | 306 (79.48)  | 136 (78.61)   |       |
| Size, n (%)               |                |              | < 0.001       |       |
| ≤ 5                       | 360 (64.52)    | 272 (70.75)  | 88 (50.87)    |       |
| > 5                       | 198 (35.48)    | 113 (29.25)  | 85 (49.13)    |       |
| Number, n (%)             |                |              | 0.518         |       |
| Solitary                  | 468 (83.87)    | 326 (84.68)  | 142 (82.08)   |       |
| Multiple                  | 90 (16.13)     | 59 (15.32)   | 31 (17.92)    |       |
| Vascular invasion, n (%)  |                |              | < 0.001       |       |
| No                        | 389 (69.71)    | 286 (74.29)  | 103 (59.54)   |       |
| Yes                       | 169 (30.29)    | 99 (25.71)   | 70 (40.46)    |       |
| Tumor capsule, n (%)      |                |              | 0.962         |       |
| Absence                   | 354 (63.44)    | 245 (63.64)  | 109 (63.01)   |       |
| Presence                  | 204 (36.56)    | 140 (36.37)  | 64 (36.99)    |       |
| Differential, n (%)       |                |              | 0.042         |       |
| Good                      | 184 (32.97)    | 269 (69.87)  | 105 (60.69)   |       |
| Moderate/poor             | 374 (67.03)    | 116 (30.13)  | 68 (39.31)    |       |
| BCLC, n (%)               |                |              | < 0.001       |       |
| A                         | 344 (61.65)    | 260 (67.53)  | 84 (48.55)    |       |
| B                         | 176 (31.54)    | 108 (28.05)  | 68 (39.30)    |       |
| C                         | 38 (6.81)      | 17 (4.42)    | 21 (12.14)    |       |
| GGT, n (%)                |                |              | < 0.001       |       |
| ≤ 50                      | 272 (48.75)    | 261 (67.79)  | 11 (6.36)     |       |
| > 50                      | 286 (51.25)    | 124 (32.21)  | 162 (93.64)   |       |
| ALBI Grade, n (%)         |                |              | 0.007         |       |
| A                         | 399 (71.51)    | 289 (75.06)  | 110 (63.58)   |       |
| B                         | 159 (28.50)    | 96 (24.90)   | 63 (36.42)    |       |

ALT, Alanine aminotransferase; TB, Total Bilirubin; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; GGT, γ-Glutamyl Transpeptidase; ALBI grade, Albumin-Bilirubin Grade
differentiation (OR: 3.44; 95% CI 2.35, 5.04; P < 0.001), BCLC B (OR: 2.95; 95% CI 2.59, 3.002), pathological differentiation (OR: 3.44; 95% CI 2.35, 5.04; P < 0.001), BCLC B < 0.0001); ALBI (OR: 2.46, 3.43; P < 0.67).

In further multivariate logistic regression, GGT/ALT (OR: 1.60, 95% CI 1.05, 2.43; P = 0.03) was still listed as an independent risk factor for vascular invasion. The other indicators included age (OR: 0.44, 95% CI 0.27, 0.74; P < 0.001), serum AFP (OR: 1.63; 95% CI 1.06, 2.51; P = 0.026), tumour size (OR: 2.15; 95% CI 1.42, 3.24; P < 0.001), tumour capsule (OR: 1.64; 95% CI 1.09, 2.47; P = 0.018), pathological differentiation (OR: 2.90; 95% CI 1.93, 4.36; P < 0.001), BCLC B (OR: 2.62; 95% CI 2.21, 3.03; P < 0.001), and, as shown in Table 2. The results demonstrated that GGT/ALT was an independent risk factor for predicting vascular invasion in HCC.

In those variables, pathological features were all positively associated with vascular invasion, which was shown to be linked with more severe tumour situations. The associated factors included tumour size, tumour capsule and pathological differentiation. Three scoring criteria, BCLC and GGT/ALT, were also positively associated with vascular invasion, while ALBI was not related. Interestingly, age was negatively related to vascular invasion, which means that younger patients had a greater proclivity to combine with vascular invasion.

Correlation between GGT/ALT and HCC related factors

The ROC curve of the GGT/ALT ratio in the diagnosis of vascular invasion was plotted and illustrated its predictive value (Fig. 2). The optimal cut-off value of GGT/ALT in the diagnosis of vascular invasion was 2.95 by calculating the Youden index of the ROC curve. Based on this cut-off value of GGT/ALT, the patients were classified into a low group (n = 365) and a high group (n = 193) for further investigations.

The correlations between the GGT/ALT ratio and clinicopathological parameters were examined, as shown in Table 1. The results indicated that the high GGT/ALT group was significantly associated with vascular invasion (P < 0.001), and the other related parameters included male sex (P = 0.003), ALT < 56 U/L (P < 0.001), GGT > 50 U/L (P < 0.001), tumour volume > 5 cm (P < 0.001), moderate/poor pathological differentiation (P = 0.042), more severe BCLC (P < 0.001) and ALBI grade (P = 0.007). The findings indicated that of the 87 patients with elevated ALT levels, 87 (98.85%) belonged to the low GGT/ALT group, with just 1 patient belonging to the high group. The distribution of GGTs also exhibited comparable characteristics. In a total of 272 patients with GGT ≤ 50 U/L, 261 patients (95.96%) belonged to the low GGT/ALT group. In addition, GGT/ALT also presented a good correlation with tumour severity, which included size, differentiation and classification scores.

| Risks       | Univariate analysis | Multivariate analysis |
|-------------|---------------------|-----------------------|
|             | OR (95% CI)         | P                     | OR (95% CI) | P     |
| Age, n (%)  |                     |                       |             |       |
| ≤ 60        | Reference            |                       | Reference   |       |
| > 60        | 0.46 (0.29, 0.74)    | < 0.001               | 0.44 (0.27, 0.74) | 0.001 |
| Sex, n (%)  |                     |                       |             |       |
| Female      | Reference            |                       |             |       |
| Male        | 1.36 (0.8, 2.32)     | 0.245                 |             |       |
| Albumin, n (%) |                   |                       |             |       |
| ≤ 40        | Reference            |                       |             |       |
| > 40        | 1.26 (0.88, 1.81)    | 0.208                 |             |       |
| TB, n (%)   |                     |                       |             |       |
| ≤ 20        | Reference            |                       |             |       |
| > 20        | 0.97 (0.53, 1.77)    | 0.916                 |             |       |
| AFP, n (%)  |                     |                       |             |       |
| ≤ 400       | Reference            |                       | Reference   |       |
| > 400       | 2.3 (1.56, 3.4)      | < 0.001               | 1.63 (1.06, 2.51) | 0.026 |
| Cirrhosis, n (%) |                |                       |             |       |
| No          | Reference            |                       |             |       |
| Yes         | 1.24 (0.79, 1.97)    | 0.344                 |             |       |
| Size, n (%) |                     |                       |             |       |
| ≤ 5         | Reference            |                       |             |       |
| > 5         | 2.96 (2.04, 4.31)    | < 0.001               | 2.15 (1.42, 3.24) | < 0.001 |
| Number, n (%) |                   |                       |             |       |
| Solitary    | Reference            |                       |             |       |
| Multiple    | 1.68 (1.05, 2.68)    | 0.032                 | 1.44 (0.85, 2.41) | 0.175 |
| Tumor capsule, n (%) |   |                       |             |       |
| Absence     | Reference            |                       |             |       |
| Presence    | 1.79 (1.24, 2.59)    | 0.002                 | 1.64 (1.09, 2.47) | 0.018 |
| Differential, n (%) |        |                       |             |       |
| Good        | Reference            |                       |             |       |
| Moderate/poor |                   |                       |             |       |
| BCLC, n (%) |                     |                       |             |       |
| A           | Reference            |                       |             |       |
| B           | 2.95 (2.46, 3.43)    | < 0.001               | 2.62 (2.21, 3.03) | < 0.001 |
| C           | 3.02 (2.63, 3.72)    | < 0.001               | 2.76 (2.33, 3.15) | < 0.001 |
| ALBI Grade, n (%) |         |                       |             |       |
| A           | Reference            |                       |             |       |
| B           | 1.95 (1.23, 2.67)    | 0.003                 | 1.44 (0.93, 2.21) | 0.1   |
| GGT/ALT     |                     |                       |             |       |
| ≤ 2.95      | Reference            |                       | Reference   |       |
| > 2.95      | 1.96 (1.34, 2.87)    | < 0.001               | 1.60 (1.05, 2.43) | 0.030 |

ALT, Alanine aminotransferase; TB, Total Bilirubin; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; ALBI grade, Albumin-Bilirubin Grade; GGT, γ-Glutamyl Transpeptidase; ALT, Alanine aminotransferase
Next, by using subgroup analysis, we explored the heterogenetic prediction value of GGT/ALT in different subgroups (Fig. 3). The results showed that GGT/ALT had better predictive effects in subgroups of age both \( \leq 60 \) years (OR: 1.75; 95% CI 1.14, 2.68; \( P = 0.011 \)) and > 60 years (OR: 3.42; 95% CI 1.41, 8.26; \( P = 0.006 \)), male (OR: 2.2; 95% CI 1.47, 3.29; \( P < 0.001 \)), albumin \( \leq 40 \) g/L (OR: 2.25; 95% CI 1.33, 3.81; \( P = 0.003 \)), TB \( \leq 20 \) μmol/L (OR: 1.94; 95% CI 1.3, 2.9; \( P = 0.001 \)), AFP \( \leq 400 \) ng/mL (OR: 2.42; 95% CI 1.51, 3.88; \( P < 0.001 \)), cirrhosis (OR: 1.91; 95% CI 1.25, 2.92; \( P = 0.003 \)), tumour size \( \leq 5 \) cm (OR: 2.18; 95% CI 1.27, 3.75; \( P = 0.005 \)), solitary tumour (OR: 1.92; 95% CI 1.26, 2.93; \( P = 0.003 \)), tumour capsule presence (OR: 1.86; 95% CI 1.02, 3.4; \( P = 0.044 \)) or absence (OR: 2.07; 95% CI 1.26, 3.4; \( P = 0.004 \)), moderate/poor pathological differentiation (OR: 2.16; 95% CI 1.29, 3.64; \( P = 0.004 \)), and ALBI stage A (OR: 1.93; 95% CI 1.2, 3.11; \( P = 0.007 \)). In general, the negative predictive value of GGT/ALT was relatively higher in the subgroups above, such as males, older patients, smaller tumour sizes, solitary tumours, etc.

Cox regression and survival analysis associated with the GGT/ALT ratio

Cox regression and survival analyses were conducted to assess the prognostic factors and confirm the prognostic value of GGT/ALT for OS and DFS. For the analysis of OS, univariate and multivariate Cox regression analyses were performed, and a higher GGT/ALT ratio (OR: 2.27; 95% CI 1.25, 4.15; \( P = 0.007 \)), moderate/poor differentiation (OR: 1.36; 95% CI 1.01, 1.83; \( P = 0.040 \)), and BCLC grade C (OR: 2.75; 95% CI 1.51, 5.04; \( P = 0.001 \)), as shown in Fig. 4. Intestinally, ALBI did not demonstrate a significant prognostic value of OS (\( P = 0.375 \)). Subsequently, an OS curve of GGT/ALT was drawn with a total follow-up time of 72 months. The results illustrated that the OS rate of the higher GGT/ALT group decreased significantly (\( P < 0.0001 \)) during the whole follow-up time. The 5-year OS rates were 56.07% in the high group and 72.73% in the low group, as shown in Fig. 5.

For the analysis of DFS, higher GGT/ALT (OR: 1.32; 95% CI 1.02, 1.70; \( P = 0.031 \)) was also outlined as a potential predictor by Cox regression analysis. The other factors included cirrhosis (OR: 1.65; 95% CI 1.17, 2.31; \( P = 0.004 \)), larger tumour size (OR: 1.85; 95% CI 1.09, 3.15; \( P = 0.024 \)) and BCLC grade C (OR: 2.42; 95% CI 1.5, 3.82; \( P = 0.001 \)).
CI 1.44, 4.07; \( P < 0.001 \) (Fig. 6). In this section, ALBI was also omitted from the significant predictors of DFS (\( P = 0.717 \)). The DFS curve of GGT/ALT yielded that the DFS rate of the higher GGT/ALT group was significantly lower, similar to the OS rate (\( P < 0.0001 \)), as shown in Fig. 7. The 5-year DFS rates of the high and low GGT/ALT groups were 43.35% and 58.70%, respectively.

**PSM of GGT/ALT for vascular invasion prediction**

To avoid the interference of other clinical parameters, PSM was used to match the data of the high and low GGT/ALT groups. After matching, there were 93 patients in the low and high GGT/ALT groups. In the original data, differences in distributions were characterized in several variables, including sex (SD = 0.302), ALT (SD = 0.727), albumin (SD = 0.184), tumour size (SD = 0.469), tumour differentiation (SD = 0.194), BCLC (SD = 0.424), GGT (SD = 1.648) and ALBI grade (SD = 0.251). After matching, there was no significant difference in the distribution between the two groups except cirrhosis (SD = 0.132), as shown in Table 3.

After matching, univariate logistic analysis was performed to evaluate the potential risk factors in the prediction of vascular invasion in HCC. The results showed that GGT/ALT (OR: 1.86; 95% CI 1.23, 3.33; \( P = 0.037 \)) was still correlated with vascular invasion. The other risk factors comprised age (OR: 0.36; 95% CI 0.15, 0.87; \( P = 0.015 \)), AFP (OR: 2.11; 95% CI 1.08, 4.12; \( P = 0.029 \)), tumour size (OR: 2.68; 95% CI 1.42, 5.07; \( P = 0.002 \)), tumour capsule (OR: 2.05; 95% CI 1.09, 3.87; \( P = 0.026 \)), pathological differentiation (OR: 4.71; 95% CI 2.42, 9.17;
### Table 3  Absolute standardized differences before and after propensity score matching

| Variables                      | Before matching | After matching | SD | SD |
|-------------------------------|-----------------|----------------|----|----|
|                               | Low (n = 365)   | High (n = 193) | Low (n = 93) | High (n = 93) |
| Age, n (%)                    |                 |                | 0.003 | 0.077 |
| ≤ 60                          | 291 (75.58)     | 131 (75.72)    | 73 (78.49) | 70 (75.27) |
| > 60                          | 94 (24.42)      | 42 (24.28)     | 20 (21.51) | 23 (24.73) |
| Sex, n (%)                    |                 |                | 0.302 | 0.032 |
| Female                        | 70 (18.18)      | 14 (8.09)      | 12 (12.90) | 13 (13.98) |
| Male                          | 315 (81.82)     | 159 (91.91)    | 81 (87.10) | 80 (86.02) |
| ALT, n(%)                     | 0.727 | <0.001 | 0.032 | <0.001 |
| ≤ 56                          | 299 (77.66)     | 172 (99.42)    | 92 (98.92) | 92 (98.92) |
| > 56                          | 86 (22.34)      | 1 (0.58)       | 1 (1.08)   | 1 (1.08)   |
| Albumin, n (%)                |                 |                | 0.184 | 0.086 |
| ≤ 40                          | 211 (54.81)     | 79 (45.66)     | 49 (52.69) | 45 (48.39) |
| > 40                          | 174 (45.19)     | 94 (54.34)     | 44 (47.31) | 48 (51.61) |
| TB, n (%)                     | 0.054 | 0.077 | 0.077 | 0.077 |
| ≤ 20                          | 349 (90.65)     | 154 (89.02)    | 86 (92.47) | 84 (90.32) |
| > 20                          | 36 (9.35)       | 19 (10.98)     | 7 (7.53)   | 9 (9.68)   |
| AFP, n (%)                    |                 |                | 0.086 | 0.023 |
| ≤ 400                         | 282 (73.25)     | 120 (69.36)    | 65 (69.89) | 64 (68.82) |
| > 400                         | 103 (26.75)     | 53 (30.64)     | 28 (30.11) | 29 (31.19) |
| Cirrhosis, n (%)              |                 |                | 0.021 | 0.132 |
| No                            | 79 (20.52)      | 37 (21.39)     | 17 (18.28) | 22 (23.66) |
| Yes                           | 306 (79.48)     | 136 (78.61)    | 76 (81.72) | 71 (76.34) |
| Size, n (%)                   |                 |                | 0.469 | 0.088 |
| ≤ 5                           | 272 (70.75)     | 88 (50.87)     | 61 (56.99) | 49 (52.69) |
| > 5                           | 113 (29.35)     | 85 (49.13)     | 40 (43.01) | 44 (47.31) |
| Number, n (%)                 |                 |                | 0.07  | <0.001 |
| Solitary                      | 326 (84.68)     | 142 (82.08)    | 77 (82.80) | 77 (82.80) |
| Multiple                      | 59 (15.32)      | 31 (17.92)     | 16 (17.20) | 16 (17.20) |
| Tumor capsule, n (%)          | 0.013 | 0.091 | 0.091 | 0.091 |
| Absence                       | 245 (63.64)     | 109 (63.01)    | 64 (68.82) | 60 (64.52) |
| Presence                      | 140 (36.37)     | 64 (36.99)     | 29 (31.18) | 33 (35.48) |
| Differential, n (%)           | 0.194 | 0.067 | 0.067 | 0.067 |
| Good                          | 269 (69.87)     | 105 (60.69)    | 32 (34.41) | 35 (37.63) |
| Moderate/poor                 | 116 (30.13)     | 68 (39.31)     | 61 (65.59) | 58 (62.37) |
| BCLC, n (%)                   |                 |                | 0.424 | 0.092 |
| A                             | 260 (67.53)     | 84 (48.55)     | 51 (54.84) | 51 (54.84) |
| B                             | 108 (28.05)     | 68 (39.3)      | 37 (39.78) | 35 (37.63) |
| C                             | 17 (4.42)       | 21 (12.14)     | 5 (5.38)   | 7 (7.53)   |
| GGT, n (%)                    | 1.648 | <0.001 | 0.092 | <0.001 |
| ≤ 50                          | 261 (67.79)     | 11 (6.36)      | 11 (11.83) | 11 (11.82) |
| > 50                          | 124 (32.21)     | 162 (93.64)    | 82 (88.17) | 82 (88.17) |
| ALBI Grade, n (%)             | 0.251 | 0.024 | 0.024 | 0.024 |
| A                             | 289 (75.06)     | 110 (63.58)    | 65 (69.89) | 66 (70.97) |
| B                             | 96 (24.94)      | 63 (36.42)     | 28 (30.11) | 27 (29.03) |

ALT, Alanine aminotransferase; TB, Total Bilirubin; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; GGT, γ-Glutamyl Transpeptidase; ALBI grade, Albumin-Bilirubin Grade
Our study demonstrated the GGT/ALT ratio as an independent predictive biomarker for vascular invasion in HBV-related HCC. After grouping patients with a cut-off value of 2.95, the high GGT/ALT group showed positive predictive value for vascular invasion, higher tumour severity, and lower DFS and OS in HCC patients. Further sensitivity analysis, including subgroup analysis and PSM, was performed and demonstrated GGT/ALT as an independent predictor for vascular invasion in HCC patients.

Vascular invasion is one of the major factors leading to poor prognosis of HCC, thus severely influencing the treatment effect of resection surgery [18]. Therefore, timely and accurate evaluations are pivotal for guiding therapeutic approaches and improving survival. As a main aetiology of HCC, HBV infection has been proven to be an important causative agent of vascular invasion in HCC patients.

HBV infection leads to multiple pathophysiological alterations, including DNA oxidative damage, liver cell necrosis, inflammatory responses, cytokine synthesis and release, fibrosis and tumour tumorigenesis [19]. In this process, HBV X protein (HBx) has been found to be related to MVI development involved in postoperative recurrence [20, 21]. Yang et al. [10] found that HBV-positive patients were more prone to develop vascular invasion in HCC. In further clinical studies, Lei et al. [9] discovered that a preoperative HBV DNA load larger than 104 IU/mL was an independent risk factor for vascular invasion in HBV-related HCC. Wei et al. [22] further summarized that both infection and active replication of HBV were associated with inflammatory injuries, the occurrence of vascular invasion and cancer metastasis in liver cancer. In addition to aggravating the progression and vascular invasion of HCC, Sarbarzeh et al. [23] also discovered that hepatitis may result in severe psychological issues. Considering the increased risk of vascular invasion associated with HBV infection, it is critical to predict the vascular invasion in HBV-related HCC.

Among the examinations, GGT and ALT are adopted broadly in the evaluation of liver pathology [24–28]. GGT can mediate the production of ROS, promote cell growth and proliferation [29] and is often elevated in liver diseases such as hepatitis, cancer and vascular invasion [25, 26, 30]. ALT is also known as a marker of liver dysfunction and inflammation, which was found to be associated with recurrence and poor survival of HBV-related HCC [31, 32].

### Table 4 Univariate logistic regression associated with vascular invasion after PSM

| Risks                        | Univariate analysis | P      |
|------------------------------|---------------------|--------|
| Age, n (%)                   | OR (95% CI)         | P      |
| ≤ 60                         | Reference           |        |
| > 60                         | 0.36 (0.15, 0.87)   | 0.015  |
| Sex, n (%)                   |                     |        |
| Female                       | Reference           |        |
| Male                         | 1.58 (0.6, 4.2)     | 0.342  |
| Albumin, n (%)               |                     |        |
| ≤ 40                         | Reference           |        |
| > 40                         | 1.37 (0.74, 2.56)   | 0.315  |
| TB, n (%)                    |                     |        |
| ≤ 20                         | Reference           |        |
| > 20                         | 1.6 (0.5, 5.12)     | 0.417  |
| AFP, n (%)                   |                     |        |
| ≤ 400                        | Reference           |        |
| > 400                        | 2.11 (1.08, 4.12)   | 0.029  |
| Cirrhosis, n (%)             |                     |        |
| No                           | Reference           |        |
| Yes                          | 0.93 (0.42, 2.08)   | 0.864  |
| Size, n (%)                  |                     |        |
| ≤ 5                          | Reference           |        |
| > 5                          | 2.68 (1.42, 5.07)   | 0.002  |
| Number, n (%)                |                     |        |
| Solitary                     | Reference           |        |
| Multiple                     | 1.24 (0.6, 2.55)    | 0.567  |
| Tumor capsule, n (%)         |                     |        |
| Absence                      | Reference           |        |
| Presence                     | 2.05 (1.09, 3.87)   | 0.026  |
| Differential, n (%)          |                     |        |
| Good                         | Reference           |        |
| Moderate/poor                | 4.71 (2.42, 9.17)   | <0.001 |
| BCLC, n (%)                  |                     |        |
| A                            | Reference           |        |
| B                            | 2.61 (1.32, 5.15)   | 0.006  |
| C                            | 2.88 (2.18, 3.42)   | <0.001 |
| ALBI Grade, n (%)            |                     |        |
| A                            | Reference           |        |
| B                            | 1.27 (0.65, 2.46)   | 0.485  |
| GGT/ALT ≤ 2.95               | Reference           |        |
| > 2.95                       | 1.86 (1.23, 3.33)   | 0.037  |

TB, Total Bilirubin; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer staging; ALBI grade, Albumin-Bilirubin Grade; GGT, γ-Glutamyl Transpeptidase; ALT, Alanine aminotransferase

P<0.001, BCLC grade B (OR: 2.61; 95% CI 1.32, 5.15; P=0.006), and grade C (OR: 2.88; 95% CI 2.18, 3.42; P<0.001), as shown in Table 4. Additionally, the ALBI grade was not significantly associated with vascular invasion after PSM (P=0.485). The results confirmed GGT/ALT as a good predictive value for vascular invasion.
However, the changes in different biomarkers were not equally accompanied by fluctuations in inflammatory responses. In HBV-related HCC patients, the prediction value of GGT for vascular invasion might be interfered by chronic inflammation and poor liver reserves associated with HBV infection. Therefore, the combination of GGT/ALT might exert better predictive accuracy than using GGT alone [33].

Ebling et al. [11] disclosed that a higher GGT/ALT ratio could predict a worse prognosis in chronic hepatitis C. The research of Tarantino et al. [12] further supported this idea by the discoveries that a lower GGT/ALT ratio is an independent predictor of antiviral therapy response. Consequently, GGT/ALT could reflect the hepatitis severity such as prognosis and therapy responses, which made it possible to predict hepatitis-induced HCC. Additionally, previous research also indicated that the high-level GGT/ALT ratio was associated more with tumour burden rather than inflammatory hepatitis parameters [13].

Several studies have evaluated the predictive value of GGT/ALT in liver cancer. Yang et al. [10] observed that hepatitis B patients with a higher GGT/ALT ratio have an increased risk of developing primary hepatic malignancy. Additionally, it was documented in HBV-related HCC patients with Child–Pugh A class that an elevated GGT/ALT ratio was associated with more severe tumour burden, including tumour size, vascular invasion, tumour capsule, and shortened survival time [13]. However, the study above generally focused on the predictive value of GGT/ALT for tumour severity, in which vascular invasion is just a part of the symptoms. Therefore, it is still debatable whether GGT/ALT remains a good predictor of vascular invasion in HCC when evaluated independently. Therefore, we focused on the first time on the risk factors for vascular invasion and investigated the independent predictive value of GGT/ALT. Combining the pathological role of HBV infection in vascular invasion and thus in HCC progression and the predictive value of GGT/ALT in both hepatitis B and HCC, we conducted this study to confirm whether GGT/ALT is an independent predictive factor of vascular invasion and outcomes in HBV-infected HCC.

As mentioned above, GGT/ALT has the ability to predict vascular invasion in HCC. However, the different distributions of characteristics among HCC patients increased the heterogeneity and might lead to false positive results. Therefore, sensitivity analysis, including subgroup analysis and PSM, was conducted. In the subgroup analysis, the predictive value of GGT/ALT was examined effectively in most subgroups. The insignificant predictive value in other subgroups might be attributed to the relatively small number of cases, and this could be confirmed through a larger database in the future. Moreover, PSM was employed to balance the distributions of variables between the high and low GGT/ALT groups. After matching, GGT/ALT was still listed as an independent risk factor for vascular invasion, which proved the predictive value of the ratio alone.

Currently, there is no authoritative explanation for the predictive value of GGT/ALT. One possible hypothesis is proposed as follows: GGT is affected by both inflammation and tumours, while ALT is relatively more responsive to hepatic inflammation and liver functions. Although hepatitis in HCC patients has often been controlled before resection, GGT and ALT might still be interfered with by residual HBV infection or surgical stimulus. Therefore, the ratio of GGT/ALT could reflect the stages of primary tumour progression more precisely by minimizing the interference of inflammation. In addition, decreased ALT also indicated an increased mortality rate in people aged over 60 years because of the depletion of liver function reserve, which could explain the positive correlation between the GGT/ALT ratio and worse prognosis [34]. Another potential explanation is that GGT/ALT ratio was also confirmed as an independent predictor of antiviral therapy response and prognosis in chronic hepatitis, which was associated with an increased risk of tumorigenesis and vascular invasion [11, 12].

In addition to HBV, the etiology of HCC also includes hepatitis C virus (HCV), food contaminated with aflatoxin, heavy drinking, obesity, smoking, type 2 diabetes, etc. [1]. Considering the degree of inflammation and vascular invasion may vary among the different etiologies, the predictive value of GGT/ALT would also be investigated respectively in the future.

In clinical practice, we often get perplexed by the fact that different patients may have totally dissimilar vascular invasions and related prognosis. However, current assessment techniques, such as CT scans and tumour markers, are insufficient to detect high risk patients. BCLC classification has also exhibited good predictive value in HCC. However, BCLC is relatively difficult to address, which limits its clinical use. As a powerful complement to imaging examination, scoring systems and other screening methods [35], our study provided a simple and feasible monitoring tool to assess vascular invasion, guide the surgical approach and predict the outcomes of HCC, which makes it easier to manage patients. With more indicators identified in the future, the evaluation model for HCC vascular invasion will be continuously refined with the input of further experimental data.

In addition to GGT/ALT, there are many other biomarkers of vascular invasion, such as Vascular-endothelial cadherin (CDH5), Angiopoietin-2 (ANGPT2), ETS-related gene (ERG), etc. [36]. Relatively, serum
GGT/ALT is easier to obtain and measure in clinical use. Therefore, it could be used in the preoperative evaluation of vascular invasion, postoperative follow-up, recurrence surveillance, and prognostic assessment. As contrast, tissue biomarkers might have better potential diagnostic performance and long-term prognostic value. However, potential bias also existed according to distinct parts of tissue and different pathologists. The specimen collection during surgery also restricts its preoperative assessment. Therefore, it does require long-term and extensive research.

This study still had several limitations. First, this study only involves a single centre. More cases from different centres and regions are required in the future. Second, this study is a retrospective study, which may lead to selection bias. This may be further verified by large-scale, randomized, controlled trials in the future.

Conclusion
Our study proposed relatively reliable evidence in proving the prognostic value of GGT/ALT. As a cheap and convenient biomarker, GGT/ALT is an independent predictor of vascular invasion and outcome in HBV-related HCC patients undergoing resection surgery. As a screening tool, GGT/ALT could help to optimize the treatment strategies for HCC patients and improve survival after surgery.

Abbreviations
HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; CT: Computed Tomography; AFP: a-Fetoprotein; GGT: γ-Glutamyl transferase; ALT: Alanine transaminase; ROS: Reactive oxygen species; TACE: Transarterial chemoembolization; OS: Overall survival; DFS: Disease-free survival; TB: Total bilirubin; BCLC: Barcelona Clinic Liver Cancer; ALBI: Albumin-Bilirubin; HBsAg: Hepatitis B virus surface antigen; ROC: Receiver operating characteristic; PSM: Propensity score matching; MVI: Microvascular invasion; HCV: Hepatitis C virus; CDH5: Vascular endothelial cadherin; ANGPT2: Angiopoietin-2; ERG: ETS-related gene.

Acknowledgements
We are thankful to Manghua Xu, Tao Qin, Jian Li and Dengyu Wang for providing excellent research conditions and Shuangjian Qiu for the construction of the database.

Authors’ contributions
ZZ, YM and ML were involved in the program plan and drafted the manuscript. JL, YZ and XM participated in the data collection and analysis. HL and LZ participated the data collection. CZ and XQ made substantial contributions to the manuscript and the analysis of data. HH, XL, QF and ZZ participated in drafting or revising the work. All authors have given final approval of the version to be published. All authors agreed to be accountable for all aspects of the manuscript. All authors read and approved the final manuscript.

Funding
This study is financially supported by the National Natural Science Fund of China (Project No. 81970526, 81900550 and 81770599) and Fundamental research program funding of Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine (lyzj116). The funding body had no role in the design of the study and collection, analysis, interpretation of data or preparation of the manuscript.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available, as the data are being used in the next study but are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The experimental protocol was established according to the ethical guidelines of the Helsinki Declaration and was approved by the Fudan University Affiliated Zhongshan Hospital Ethics Committee. Informed consent was waived for this non-interventional, observational, and retrospective study by the Ethics Committees, in which the patient data used were kept strictly confidential.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 15 April 2021   Accepted: 15 September 2021
Published online: 28 September 2021

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.
2. Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D. Cancer epidemiology and prevention. Oxford: Oxford University Press; 2017.
3. Poen DJ, Anderson BO, Chen LT, Tanaka K, Lau WY, van Cutsem E, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111–8. https://doi.org/10.1016/s1470-2045(09)70241-4.
4. Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillion AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39. https://doi.org/10.1245/s10434-012-2513-1.
5. Shi J, Lai ECH, Li N, Guo W-X, Xue J, Lau WY, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010;17:2073–80. https://doi.org/10.1245/s10434-010-0940-4.
6. Del Perea PE, Bernal Belledo C, Sendin Matin M, Cepeda Franco C, Alamo Martinez JM, Suarez Artacho G, et al. Recurrent hepatocellular carcinoma after liver transplantation: analysis of risk factors. Transplant Proc. 2016;48:2990–3. https://doi.org/10.1016/j.transproceed.2016.09.020.
7. Fujiyama S, Aishima S, Iguchi T, Mano Y, Taketomi A, Shiraishi E, et al. Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma. Hum Pathol. 2011;42:1531–8. https://doi.org/10.1016/j.humpath.2010.12.016.
8. Zhou L, Rui J-A, Wang S-B, Chen S-G, Qu Q. Risk factors of microvascular invasion, portal vein tumor thrombosis and poor post-resectional survival in HBV-related hepatocellular carcinoma. Hepatogastroenterology. 2014;61:1696–701.
9. Lei Z, Li J, Wu D, Xia Y, Wang Q, Si A, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg. 2016;151:356–63. https://doi.org/10.1001/jamasurg.2015.4257.
10. Yang P, Li Q-J, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF–β–mitf-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303. https://doi.org/10.1016/j.cccr.2012.07.023.
11. Ebeling F. Factors predicting interferon treatment response in patients with chronic hepatitis C: late viral clearance does not preclude a sustained response. Am J Gastroenterol. 2001;96:1237–42. https://doi.org/10.1016/s0002-9270(00)02042-2.
12. Tarantino G, Sorrentino P, Conca P, Perrella A, RaguCCI P, Perrella O. Low daily dosage of interferon for 1 year after HBV-related end-therapy for chronic hepatitis B. J Hepatol. 2010;53:681–7. https://doi.org/10.1016/j.jhep.2010.07.030.
response. A randomized-controlled study. Liver Int. 2003;23:413–9. https://doi.org/10.1046/j.1478-3231.2003.00871.x.

13. Ju M-J, Qiu S-J, Fan J, Zhou J, Gao Q, Cai M-Y, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635–42. https://doi.org/10.1007/s00535-009-0505-x.

14. Yang J-G, He X-F, Huang B, Zhang H-A, He Y-K. Rule of changes in serum GGT levels and GGT/ALT and AST/ALT ratios in primary hepatic carcinoma patients with different AFP levels. Cancer Biomark. 2018;21:743–6. https://doi.org/10.3233/CBM-170988.

15. Llovet JM, Bru C, Brux J. Prognosis of hepatic hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38. https://doi.org/10.1055/s-2007-1007122.

16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503. https://doi.org/10.1002/1097-0142(195405)7:3%3c462::aid-cncr2820070308%3e3.0.co;2-e.

17. Johnson PJ, Berhane S, Kagebayaishi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8. https://doi.org/10.1200/JCO.2014.57.9151.

18. Li S-H, Guo Z-X, Xiao C-Z, Wei W, Shi M, Chen Z-Y, et al. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev. 2013;14:4759–63. https://doi.org/10.7314/apjcp.2013.14.8.4759.

19. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tioiari P. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris). 2010;58:278–87. https://doi.org/10.1016/j.patbio.2010.05.001.

20. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012;48:1977–87. https://doi.org/10.1016/j.ejca.2012.01.015.

21. Xu J, Liu H, Chen L, Wang S, Zhou L, Yun X, et al. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 2012;143:199-212.e4. https://doi.org/10.1053/j.gastro.2012.03.053.

22. Wei X, Li N, Li S, Shi J, Guo W, Zheng Y, Cheng S. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer. 2017;17:1304. https://doi.org/10.1186/s12885-017-3293-6.

23. Ahmadi Sarbarzeh P, Karimi S, Jalilian M, Mosafer H. Depression, anxiety, and active replication promote the formation of vascular invasion in multinoiodular hepatocellular carcinoma. Eur J Surg Oncol. 2013;39:858–64. https://doi.org/10.1016/j.ejso.2013.04.003.

24. Wang K, Li L, Wu Y, Yang Y, Chen J, Zhang D, et al. Increased serum gamma-glutamyltransferase levels are associated with ventricular instability in type 2 diabetes. Endocrine. 2016;52:63–72. https://doi.org/10.1007/s12020-015-0760-1.

25. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70. https://doi.org/10.1002/hep.22109.

26. Kunutsor SK, Apekey TA, van Hemelrijck M, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2015;136:1162–70. https://doi.org/10.1002/ijc.29894.

27. Carr BI, Pancoska P, Branch RA. Significance of increased serum GGT levels in HCC patients. Hepatogastroenterology. 2010;57:869–74.

28. Tarao K, Takemiyia S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatocarcinoma patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688–94. https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4%3c688::AID-CNCR5%3e3.0.CO;2-A.

29. Cheung Y-S, Chan HL, Wong J, Lee K-F, Poon TC, Wong N, Lai PB. Elevated perioperative transaminase level predicts intrahepatic recurrence in Hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31:41–9. https://doi.org/10.1016/S1097-0142(195405)7%3c462::aid-cncc2820070308%3e3.0.co;2-e.

30. Carr BI, Pancoska P, Branch RA. Significance of increased serum GGT levels in HCC patients. Hepatogastroenterology. 2010;57:869–74.

31. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMed J. 2020;2:1–7. https://doi.org/10.28991/scimedj.2020.015-0048.

32. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMed J. 2020;2:1–7. https://doi.org/10.28991/scimedj.2020.015-0048.

33. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMed J. 2020;2:1–7. https://doi.org/10.28991/scimedj.2020.015-0048.

34. Oh C-M, Won Y-J, Cho H, Lee J-K, Park BY, Jun JK, et al. Alanine aminotransferase and gamma-glutamyltransferase. Br J Biomed Sci. 2008;65:132–5. https://doi.org/10.1080/09674845.2008.11732816.

35. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, enhanced spectroscopy (RESpect) probe for childhood non-hodgkin lymphoma. SciMed J. 2020;2:1–7. https://doi.org/10.28991/scimedj.2020.015-0048.

36. Kahn BM, Lucas A, Alur RG, Wengyn MD, Schwartz GW, Li J, et al. The vascular landscape of human cancer. J Clin Invest. 2021. https://doi.org/10.7314/jcclininvest.110172/s10434-014-3724-4.